Craft Capital Management Closes 10 Million Dollar Transaction in Variant Pharmaceuticals, Inc.

Monday, December 3, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

GARDEN CITY, N.Y., Dec. 3, 2018 /PRNewswire/ -- Garden City, NY based Brokerage firm Craft

Capital Management is excited to announce they have secured and closed a 10 million dollar investment in Variant Pharmaceuticals, Inc. out of Weston, FL through an international family office.
Craft Capital has been working with the Variant team for a number of years now.  "Having a well-respected foreign entity consider a US based pharma investment, and then invest 10 million dollars in Variant Pharmaceuticals speaks volumes about Variant's team, their vision, and their drug pipeline," said Barry Kiront, CEO of Craft Capital. 

About Craft Capital Management

Craft Capital Management is a full-service broker dealer and investment bank. Areas of focus include numerous growth sectors such as biotechnology, consumer goods and services, financial services and business, technology, healthcare, medical device, and other categories. Craft Capital Management assists companies with corporate finance services, including initial public offerings, follow-on offerings, private placements, registered direct offering, corporate notes, credit lines and financial advisory services.  Additional information about Craft Capital Management LLC is available at www.craftcm.com. If you would like to inquire how Craft Capital may be able to assist with your company's financial needs, please contact us at info@craftcm.com.

About Variant Pharmaceuticals

Variant Pharmaceuticals is a clinical stage orphan drug company focusing on restoring health and transforming the lives of patients with rare diseases through innovation.  It was established in 2014, with the mission to become a leading orphan drug company.  Variant's evolving product pipeline is targeted to the $100+ billion orphan drug market. Their lead drug candidate is 2-hydroxypropyl-?-cyclodextrin (2HP?CD) for chronic treatment of two orphan indications, Focal Segmental Glomerulosclerosis (FSGS) and Alport Syndrome (AS), rare progressive forms of kidney disease.  

Related Links

http://www.craftcm.com

Cision View original content:http://www.prnewswire.com/news-releases/craft-capital-management-closes-10-million-dollar-transaction-in-variant-pharmaceuticals-inc-300758648.html

SOURCE Craft Capital Management



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store